CRISPR technology can experience failures or clinical limitations primarily due to off-target effects, where the Cas9 endonuclease inadvertently cuts unintended sections of the DNA strand, leading to potential chromosomal aberrations. Additionally, cellular delivery hurdles—such as safely routing the editing machinery to the exact target tissue within a living human body without triggering adverse immune responses or systemic inflammation—remain major technical obstacles for researchers.